Earlier this month, we highlighted Flora Growth Corp. (Nasdaq: FLGC) as a differentiated play on the Latin American (and global) cannabis market.
Although Flora Growth has reported several significant developments since it started trading on the Nasdaq, the recent trend has been mixed. Going forward, we expect the trend to shift and expect the company to receive more awareness after MKM Partners issued Flora Growth a Buy Rating and a $6 price target.
Adds Valuable Human Capital to the Team
Prior to Flora Growth receiving coverage from MKM Partners, the company appointed Dr. Annabelle Manalo-Morgan, PhD, as Lead Scientific Advisor. We believe her appointment will play an important role in the growth of the business and will be focused on furthering the research and development (R&D) of unique product formulations and educating individuals on the benefits of cannabinoid and plant-based medicine.
Dr. Annabelle has an impressive background and we are favorable on the expertise that she adds to the team. Dr. Annabelle is a cell and developmental biologist from Vanderbilt University and has a background in neuroscience from Georgetown University. She earned her PhD in Cell and Developmental Biology with a focus in Cardio-Oncology.
One of the reasons we are excited about her appointment is related to the knowledge that she has in the fields of pharmaceutical innovation and clinical trial research in medical cannabis. As the Lead Scientific Advisor for Flora Growth, Dr. Annabelle will work with the team to fill knowledge gaps that are prominent throughout the global cannabis industry.
Flora Growth’s advisory team is executing on an initiative that is expected to accelerate the production of cannabis products that have claims that are backed by scientific data. As the Lead Scientific Advisor, Dr. Annabelle will be examining the therapeutic application of cannabinoids on specific disease conditions, and we are favorable on her involvement.
Dr. Annabelle is expected to be instrumental in the future of Flora Growth’s product development, research, and educational efforts. As part of the planned R&D efforts, the company expects to start conducting clinical trials as soon as it completes the necessary protocols, and we expect this to be a catalyst for the business.
The formation of the advisory team that will be led by Dr. Annabelle is expected to streamline Flora Growth’s R&D efforts and accelerate growth initiatives as it works to launch targeted cannabis products and increase distribution across all channels.
Dr. Annabelle is focused on bringing novel cannabis products that have a superior safety profile and are more efficacious than existing treatment options to market and we will monitor how the story advances from here.
Learn More by Attending a Fireside Chat
During the last month, Flora Growth has reported several significant developments and we believe the opportunity is flying under the radar. Tomorrow, Flora Growth will be hosting a live fireside discussion between President & CEO, Luis Merchan, and Vice President of Corporate Development, James Williams.
During the discussion, they will provide an overview of the recent Hoshi and Heimat announcements, including their strategic importance to its planned international expansion as well as the expected contributions to revenue growth. Luis and James will also discuss the latest management additions and outline the company’s plan to secure valuable human capital to execute on its multi-faceted growth strategy.
To attend the event, you can use the following link: https://us02web.zoom.us/webinar/register/WN_9dTiVRXpQ0qfKOIBXJBSdQ
We expect the discussion to provide important insight on the business and plan to issue and update on Flora Growth after it. If you are interested in learning more about Flora Growth, please send an email to email@example.com with the subject “Flora Growth” to be added to our distribution list.
For the fastest access to data on Flora Growth, sign up for our free newsletter!
Pursuant to an agreement between StoneBridge Partners LLC and Flora Growth Corp. (FLGC) we have been hired for a period of 180 days beginning May 13, 2021 and ending November 13, 2021 to publicly disseminate information about (FLGC) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (FLGC) and were not issued any shares of restricted common shares. We own zero shares of (FLGC), which we purchased in the open market. We plan to sell the “ZERO” shares of (FLGC) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (FLGC) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.